ERBB2 and breast cancer: Personalized treatment of HER2-positive breast cancer and better predictive biomarkers to anticipate therapy resistance will contribute to the identification of patients that will benefit from new combinatorial therapies, paving the way for HER2-positive breast cancer precision medicine [18].